Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Bases de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Mol Cell ; 79(3): 406-415.e7, 2020 08 06.
Artículo en Inglés | MEDLINE | ID: mdl-32692975

RESUMEN

Protein secretion in eukaryotes and prokaryotes involves a universally conserved protein translocation channel formed by the Sec61 complex. Unrelated small-molecule natural products and synthetic compounds inhibit Sec61 with differential effects for different substrates or for Sec61 from different organisms, making this a promising target for therapeutic intervention. To understand the mode of inhibition and provide insight into the molecular mechanism of this dynamic translocon, we determined the structure of mammalian Sec61 inhibited by the Mycobacterium ulcerans exotoxin mycolactone via electron cryo-microscopy. Unexpectedly, the conformation of inhibited Sec61 is optimal for substrate engagement, with mycolactone wedging open the cytosolic side of the lateral gate. The inability of mycolactone-inhibited Sec61 to effectively transport substrate proteins implies that signal peptides and transmembrane domains pass through the site occupied by mycolactone. This provides a foundation for understanding the molecular mechanism of Sec61 inhibitors and reveals novel features of translocon function and dynamics.


Asunto(s)
Macrólidos/farmacología , Microsomas/química , Ribosomas/química , Canales de Translocación SEC/química , Animales , Sitios de Unión , Sistema Libre de Células/metabolismo , Perros , Expresión Génica , Células HCT116 , Células HEK293 , Humanos , Macrólidos/química , Macrólidos/aislamiento & purificación , Microsomas/metabolismo , Simulación de Dinámica Molecular , Mutación , Mycobacterium ulcerans/química , Mycobacterium ulcerans/patogenicidad , Páncreas/química , Páncreas/metabolismo , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Transporte de Proteínas , Ribosomas/metabolismo , Canales de Translocación SEC/antagonistas & inhibidores , Canales de Translocación SEC/genética , Canales de Translocación SEC/metabolismo , Homología Estructural de Proteína , Especificidad por Sustrato
2.
J Am Chem Soc ; 141(21): 8450-8461, 2019 05 29.
Artículo en Inglés | MEDLINE | ID: mdl-31059257

RESUMEN

Ipomoeassin F is a potent natural cytotoxin that inhibits growth of many tumor cell lines with single-digit nanomolar potency. However, its biological and pharmacological properties have remained largely unexplored. Building upon our earlier achievements in total synthesis and medicinal chemistry, we used chemical proteomics to identify Sec61α (protein transport protein Sec61 subunit alpha isoform 1), the pore-forming subunit of the Sec61 protein translocon, as a direct binding partner of ipomoeassin F in living cells. The interaction is specific and strong enough to survive lysis conditions, enabling a biotin analogue of ipomoeassin F to pull down Sec61α from live cells, yet it is also reversible, as judged by several experiments including fluorescent streptavidin staining, delayed competition in affinity pulldown, and inhibition of TNF biogenesis after washout. Sec61α forms the central subunit of the ER protein translocation complex, and the binding of ipomoeassin F results in a substantial, yet selective, inhibition of protein translocation in vitro and a broad ranging inhibition of protein secretion in live cells. Lastly, the unique resistance profile demonstrated by specific amino acid single-point mutations in Sec61α provides compelling evidence that Sec61α is the primary molecular target of ipomoeassin F and strongly suggests that the binding of this natural product to Sec61α is distinctive. Therefore, ipomoeassin F represents the first plant-derived, carbohydrate-based member of a novel structural class that offers new opportunities to explore Sec61α function and to further investigate its potential as a therapeutic target for drug discovery.


Asunto(s)
Glicoconjugados/farmacología , Canales de Translocación SEC/antagonistas & inhibidores , Sitios de Unión/efectos de los fármacos , Glicoconjugados/química , Humanos , Estructura Molecular , Transporte de Proteínas/efectos de los fármacos , Canales de Translocación SEC/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA